19-08-2025
Hy2Care® in the spotlight
Hy2Care is featured in LSI’s magazine, The Lens. In the article Leo Smit, CEO Hy2Care® gives insight into the technology of its CartRevive® hydrogel implant designed to restore natural cartilage in the focal knee defects and he explains his personal motivation for Hy2Care’s mission in creating a solution that gives people back their lives.
Text by Brenna Hopkins
In this interview the following topics are covered:
Personal and scientific mission – CEO Leo Smit joined Hy2Care in 2019, driven by personal motivation from his mother’s struggle with arthritis and decades of medtech expertise.
Innovative cartilage repair solution – The company’s lead product, the CartRevive hydrogel implant, is an in-situ forming hydrogel that fills cartilage defects without cutting or fixation, solidifies within 60 seconds, integrates with surrounding tissue, and supports natural healing.
Promising clinical results – In a European trial with 46 patients, The CartRevive hydrogel implant significantly improved pain and mobility scores (2.5× the threshold for clinical relevance at 12 months), with many patients returning to sports within a year.
Cost-effective scalability – The CartRevive hydrogel implant matches the tissue quality of advanced cell therapies but at just 15% of the cost, making high-quality cartilage repair more affordable and accessible.
Regulatory and commercial momentum – Hy2Care has FDA Breakthrough Device Designation (2023), IDE approval for US trials (2025), and a CE mark submission in progress.
Click here to read the full article
